Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
NINGBO INNO PHARMCHEM CO.,LTD. explores the detailed pharmacological profile of rivaroxaban, an oral direct factor Xa inhibitor, focusing on its absorption, distribution, metabolism, and excretion (ADME). Understanding these aspects is vital for its safe and effective use, and it relates to the 'pharmacology of rivaroxaban' long-tail keyword.
Absorption: Rivaroxaban is characterized by high oral bioavailability, typically around 80-100% when taken with food. This high absorption rate is a key factor contributing to its predictable pharmacokinetic behavior. Unlike some other oral anticoagulants, its absorption is not significantly affected by dietary fat content, making mealtime adherence less critical for consistent therapeutic levels.
Distribution: Once absorbed, rivaroxaban is extensively distributed in the body. It is highly bound to plasma proteins, primarily albumin, with approximately 92-95% protein binding. This high protein binding influences its distribution volume and half-life.
Metabolism: Rivaroxaban is metabolized in the liver through various pathways, with cytochrome P450 (CYP) enzymes playing a role, specifically CYP3A4, CYP2C19, and to a lesser extent, CYP1A2, CYP2A6, CYP2B6, and CYP2D6. However, a significant portion of the drug is excreted unchanged. The drug's metabolism is generally considered to have limited clinical impact concerning drug-drug interactions, a notable advantage in its pharmacological profile.
Excretion: Rivaroxaban is eliminated from the body through both renal and hepatic pathways. Approximately two-thirds of an administered dose is excreted renally as unchanged drug, while the remaining one-third is eliminated via hepatic metabolism and subsequent excretion as inactive metabolites. The drug's clearance is influenced by factors such as age, gender, and renal/hepatic function, which are important considerations for dose adjustments in specific patient groups.
The predictable ADME properties of rivaroxaban contribute significantly to its suitability for fixed-dose, once-daily administration without the need for routine laboratory monitoring. This comprehensive understanding of its pharmacological behavior is central to its success as a modern anticoagulant.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
